INS and metabolic syndrome: Pharmacological inhibition of ABHD6 causes beneficial metabolic effects in mice such as enhancement of insulin secretion and energy expenditure, thus qualifying ABHD6 as a promising target for the treatment of the metabolic syndrome and its comorbidities.